XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
  Cornea
  Cataract
  Retina
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Ophthalmology Channel
subscribe to Ophthalmology newsletter

Latest Research : Ophthalmology

   DISCUSS   |   EMAIL   |   PRINT
First description of a human HOXA1 mutation syndrome
Sep 12, 2005, 20:37, Reviewed by: Dr.

"This is the first description of a human syndrome resulting from any of the HOX genes involved in brain development, and the first report of a total loss of any HOX gene in humans,"

 
Researchers at Children's Hospital Boston, who specialize in studying the genetics of rare eye-movement disorders, have found a rare genetic syndrome whose implications go far beyond the eye, raising intriguing questions about human cardiovascular and brain development.

The syndrome involves a mutation to HOXA1, a gene that has been extensively studied in mice, but about which little is known in humans. HOXA1 belongs to a large family of HOX genes that govern very early embryonic development and the making of the body plan. HOXA1 is the first HOX gene turned on in mice, and presumably in the human body, and is involved in patterning of the growth of the head, face, and brainstem.

Mice that lack both copies of HOXA1 universally die. Until this study, no human HOXA1 mutation had ever been identified, and it was assumed that complete loss of HOXA1 function would be lethal. But the Children's investigators, led by graduate student Max Tischfield and neurologist Dr. Elizabeth Engle of the Children's Hospital Boston Program in Genomics and the Harvard Medical School Program in Neuroscience, have found living people with two mutated copies of HOXA1 -- from three different parts of the world.

"This is the first description of a human syndrome resulting from any of the HOX genes involved in brain development, and the first report of a total loss of any HOX gene in humans," says Engle, senior author of the study.

Tischfield and Engle had been studying genetic disorders that interfere with peoples' ability to move their eyes horizontally (left or right). Collaborators in Saudi Arabia alerted them to patients they'd been seeing who had not only restricted horizontal eye movement, but also deafness and motor impairments. The Saudi clinicians began to carefully reexamine their patients, while Tischfield and Engle looked at the patients' DNA to try to identify a causative gene.

All 9 patients with the syndrome (dubbed Bosley-Salih-Alorainy syndrome, or BSAS, after the Saudi discoverers) had horizontal gaze abnormalities. Eight were profoundly deaf, 3 had external ear defects, 7 had delayed motor development, and 2 met criteria for autism spectrum disorder with cognitive and behavioral impairment. In addition, 7 had malformations or complete absence of one or both internal carotid arteries, one of the two carotid arteries that are the main suppliers of blood to the brain.

DNA linkage studies and follow-up analyses all implicated HOXA1 in the syndrome. But to make the case, Tischfield and Engle needed to find HOXA1 mutations in other populations. For over a decade, Engle has been collecting large pedigrees of families with eye-movement disorders. She and Tischfield tapped this database and found a child from Turkey whose symptoms were much like those of the Saudi patients. This child also had a HOXA1 mutation, but in a different location on the gene.

Fortuitously, Engle and Tischfield also recalled a paper reporting a syndrome in 10 Native American children in Arizona that had many similarities to BSAS. They obtained these children's DNA and found that they also had a HOXA1 mutation, at yet another location on the gene. Like the people with BSAS, the children had horizontal gaze restriction, deafness, and delayed motor development, and some had loss or malformation of the carotid arteries. However, all also had breathing difficulties and mental retardation, and some had facial weakness, paralysis of the vocal cords and heart defects of a type that occur very early in embryonic development. The researchers attribute the differences between the Middle Eastern and Native American patients to environmental influences and the influence of other gene variations unique to each group.

Overall, however, the findings suggest that HOXA1 is involved in early development of the cardiovascular system, a function of the gene not previously known. "The cardiovascular malformations in people with HOXA1 mutations were never reported in mice," says Tischfield, the study's first author. "We've potentially uncovered a new developmental role for HOXA1 in vascular patterning in humans, a role that may have been overlooked in mice."

Most intriguingly, the association of both mental retardation and autism with HOXA1 mutations suggests that early malformation of the brainstem, which controls "lower" functions such as eye movement and breathing, may also lead to impairment in higher cognitive and behavioral function.

"HOXA1 is expressed in the brainstem, but we do not believe it is expressed in the higher brain (the cerebrum or cerebellum)," Tischfield notes. "But there's a lot of output from the brainstem during brain development. Serotonin comes from the brainstem, and many people believe that autism and mental retardation result from an abnormal influence of serotonin. Our paper may spark ongoing interest in how serotonin systems modulate development of the higher brain."

Interestingly, in utero exposure to thalidomide very early in pregnancy, during the time when HOXA1 is turned on, causes damage in the brainstem that mimics the HOXA1 syndrome. In addition, a previous autopsy of an autistic individual showed brainstem pathology similar to that of mice whose HOXA1 genes had been deleted.

"HOXA1 is a gene that's been looking for a disorder for a long time," says Engle. "It's one of a series of interesting genes we've stumbled on by using complex eye-movement disorders as a marker for developmental defects."
 

- Nature Genetics
 

www.childrenshospital.org

 
Subscribe to Ophthalmology Newsletter
E-mail Address:

 

Founded in 1869 as a 20-bed hospital for children, Children's Hospital Boston today is the nation's leading pediatric medical center, the largest provider of health care to Massachusetts children, and the primary pediatric teaching hospital of Harvard Medical School. In addition to 347 pediatric and adolescent inpatient beds and comprehensive outpatient programs, Children's houses the world's largest research enterprise based at a pediatric medical center, where its discoveries benefit both children and adults. More than 500 scientists, including eight members of the National Academy of Sciences, nine members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. For more information about the hospital visit: http://www.childrenshospital.org.

Related Ophthalmology News

Master Proteins Dictate Retinal Differentiation Timetable
Yellow plant pigments lutein and zeaxanthin reduce risk of age-related macular degeneration
Objective way to diagnose diseases of colour perception
Onchocerciasis treatment reduces prevalence and intensity by 38%
Antioxidants may slow retinal degeneration
Hormone Therapy Does Not Affect Age-Related Vision Loss
Eating Fish Protects Against Macular Degeneration
Research Highlights Risk Factors For Age-Related Vision Loss
How Thalamic Neurons Grab Your Attention
FDA approves ranibizumab for the treatment of wet age-related macular degeneration


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us